The viral vector purification market is experiencing significant advancement, driven by innovative technologies enhancing purification processes. These advancements streamline production, improving vector yield and quality while reducing production costs and time. Consequently, the market benefits from increased efficiency and scalability, catering to the growing demand for viral vectors in gene therapy, vaccine development, and research applications. With improved purification methods, manufacturers can ensure higher product purity, potency, and safety, meeting stringent regulatory requirements. This leads to broader adoption of viral vectors in clinical settings, accelerating the development of novel therapeutics and expanding treatment options for various diseases.
The Global Viral Vector Purification Market size which was USD 721.42 million in 2023, is expected to reach USD 2,086.99 million by 2031, and is expected to undergo a CAGR of 14.2% during the forecast period of 2024 to 2031.
Below are the Top Five Viral Vector Purification Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific is a global leader in viral vector purification solutions. Leveraging cutting-edge technologies, their products facilitate efficient and scalable purification processes for viral vectors used in gene therapy and vaccine development. With a comprehensive portfolio of chromatography resins, filtration systems, and purification platforms, Thermo Fisher enables researchers and manufacturers to achieve high yields and purity levels, meeting regulatory requirements and accelerating the development of viral vector-based therapies.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In January 2021, Thermo Fisher Scientific Inc. announced that it had completed the acquisition of Novsep’s viral vector manufacturing business in Belgium, which will help the company further diversify its market.
|
|
2.
|
Cytiva
|
Formerly GE Healthcare Life Sciences, Cytiva specializes in viral vector purification technologies. Their innovative products, such as chromatography columns and filtration membranes, enable streamlined purification processes for viral vectors, enhancing efficiency and product quality. Cytiva's expertise in bioprocessing ensures robust and scalable solutions for viral vector purification, supporting the advancement of gene therapy and vaccine manufacturing.
|
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In March 2024, Cytiva's Vice President of Technology Development, Dr. Markus Krieger, and Viral Vector Leader, Clive Glover, discussed the challenges and solutions in AAV-based gene therapy manufacturing. Addressing rising demands, Cytiva acquired CEVEC Pharmaceuticals and integrated it with Pall Corporation's life sciences division, bolstering its capacity to provide robust viral vector solutions for therapy manufacturing.
|
|
3.
|
Merck KGaA
|
Merck KGaA offers a diverse range of products and services for viral vector purification, catering to the evolving needs of the biopharmaceutical industry. Their portfolio includes chromatography resins, filtration membranes, and viral clearance solutions, ensuring efficient and reliable purification of viral vectors. Merck KGaA's commitment to innovation and quality enables researchers and manufacturers to optimize their purification processes, accelerating the development and production of viral vector-based therapeutics.
|
|
North America, Middle East and Africa, Europe, Latin America, Asia-Pacific, and Others
|
In April 2020, Merck KGaA boosted its commercial viral vector and gene therapy manufacturing capacity. This escalation in manufacturing capacity has helped the company grow its business and revenue.
|
|
4.
|
Agilent Technologies, Inc.
|
Agilent Technologies provides advanced solutions for viral vector purification, addressing the complexities of bioprocessing with precision and reliability. Their chromatography systems, filtration technologies, and analytical instruments empower researchers and manufacturers to achieve consistent purification results and meet stringent regulatory requirements. Agilent's dedication to innovation and customer support ensures that its products enable efficient and scalable purification processes for viral vectors, facilitating the development of novel gene therapies and vaccines.
|
|
Europe, North America, and Asia-Pacific
|
In July 2020, Agilent Technologies, Inc. introduced the Agilent 6545XT AdvanceBio LC/Q-TOF for characterizing viral vector particles, particularly AAVs used in gene therapy. This technology addresses challenges in maintaining therapeutic products' critical quality attributes (CQAs) by accurately characterizing viral capsid proteins through intact analysis and peptide mapping using MassHunter BioConfirm 10.0 software.
|
|
5.
|
FUJIFILM Diosynth Biotechnologies
|
FUJIFILM Diosynth Biotechnologies offers comprehensive solutions for viral vector purification, leveraging their expertise in bioprocess development and manufacturing. Using chromatography, filtration, and viral inactivation technologies, they provide robust and scalable purification processes for viral vectors used in gene therapy and vaccine production. FUJIFILM Diosynth Biotechnologies' commitment to quality and innovation ensures that their purification solutions meet the evolving needs of the biopharmaceutical industry, supporting the efficient and cost-effective manufacturing of viral vector-based therapeutics.
|
|
North America, Europe
|
In 2024, FUJIFILM Diosynth Biotechnologies excels in viral vector purification. Our adept technical teams tackle scale-up hurdles, crafting cGMP-compliant drug substance and product manufacturing processes. Our flexible development-to-manufacture approach allows seamless process optimization, enhancing safety, efficacy, and stability. We anticipate risks early, ensuring robust cGMP manufacturing. Our upstream development spans adherent and suspension cell cultures, replicating larger-scale cGMP facilities.
|
Conclusion
In conclusion, the viral vector purification market is poised for substantial growth driven by increasing demand for gene therapy treatments. Technological advancements in purification techniques present lucrative opportunities for market players to streamline production processes and enhance product efficacy. With rising investments in biopharmaceutical research and development, the market is set to flourish, catering to the growing need for safe and efficient viral vector purification solutions in the healthcare sector.
